Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222660 | 0.83 | LMNA (0.51) | PKML3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL32660807 | 0.83 | LMNA (0.51) | PKML3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3225021 | 0.81 | LMNA (0.55) | PKML3MBTL1SMN1; SMN2TDP1LMNA | |
| SCHEMBL19904763 | 0.79 | PKM (0.49) | PKML3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL19904746 | 0.78 | L3MBTL1 (0.50) | PKML3MBTL1SMN1; SMN2GLATDP1 | |
| SCHEMBL30722828 | 0.76 | PKM (0.51) | PKML3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL3222691 | 0.76 | PKM (0.51) | PKML3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL3224957 | 0.74 | L3MBTL1 (0.52) | PKML3MBTL1SMN1; SMN2LMNA | |
| SCHEMBL13430890 | 0.74 | LMNA (0.42) | PKML3MBTL1SMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL3238027 | 0.73 | PKM (0.51) | PKML3MBTL1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097428-B1 | BUTYRYLCHOLINESTERASE INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | MGP BIOTECHNOLOGIES INC (US) | 2018-02-28 | — | — | EP | disclosed |